An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

被引:28
|
作者
Pascual-Iglesias, Alejandro [1 ,2 ]
Canton, Javier [3 ]
Ortega-Prieto, Ana Maria [4 ]
Jimenez-Guardeno, Jose M. [4 ]
Regla-Nava, Jose Angel [5 ,6 ]
机构
[1] La Paz Univ Hosp, IdiPAZ, Innate Immune Response Grp, Madrid 28046, Spain
[2] La Paz Univ Hosp, IdiPAZ, Tumor Immunol Lab, Madrid 28046, Spain
[3] Int Inst Def & Secur CISDE, Seville 41007, Spain
[4] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London SE1 9RT, England
[5] Ctr Infect Dis & Vaccine Res, La Jolla Inst Immunol, La Jolla, CA 92037 USA
[6] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Dept Pathol & Microbiol, Guadalajara 44340, Mexico
来源
PATHOGENS | 2021年 / 10卷 / 08期
关键词
coronavirus; SARS-CoV-2; COVID-19; vaccine; clinical trial; pandemic; RESPIRATORY SYNCYTIAL VIRUS; ANIMAL-MODELS; CORONAVIRUS INFECTION; SARS; MERS; DISEASE; SAFETY; PATHOGENESIS; MUTATIONS; COUNTRIES;
D O I
10.3390/pathogens10081030
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients
    Liuzzo Scorpo, Maria
    Ferrante, Giuliana
    La Grutta, Stefania
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [42] SARS-CoV-2 IgG seroprevalence in personnel of the extraclinical fight against the COVID-19 pandemic
    Brune, Bastian
    Korth, Johannes
    Fessmann, Kai
    Stappert, Daniel
    Nohl, Andre
    Lembeck, Thomas
    Standl, Fabian
    Stang, Andreas
    Dittmer, Ulf
    Witzke, Oliver
    Herrmann, Anke
    Dudda, Marcel
    NOTFALL & RETTUNGSMEDIZIN, 2023, 26 (08): : 593 - 601
  • [43] Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic
    Komiyama, Makoto
    BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, 2021, 94 (05) : 1478 - 1490
  • [44] SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic
    Erensoy, Selda
    MIKROBIYOLOJI BULTENI, 2020, 54 (03): : 497 - 509
  • [45] Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
    Gonzalez-Vazquez, Luis Daniel
    Arenas, Miguel
    GENES, 2023, 14 (02)
  • [46] The Economic Impact of the SARS-COV-2 (COVID-19) Pandemic in Spain
    Pinilla, Jaime
    Barber, Patricia
    Vallejo-Torres, Laura
    Rodriguez-Mireles, Silvia
    Lopez-Valcarcel, Beatriz G.
    Serra-Majem, Luis
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (09)
  • [47] Consequences of the COVID-19/SARS-CoV-2 pandemic for gastroenterology in Germany
    Frieling, Thomas
    GASTROENTEROLOGE, 2020, 15 (06): : 498 - 505
  • [48] Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic
    Brufsky, Adam
    Lotze, Michael T.
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2379 - 2380
  • [49] COVID-19 pandemic crisis—a complete outline of SARS-CoV-2
    Sana Saffiruddin Shaikh
    Anooja P. Jose
    Disha Anil Nerkar
    Midhuna Vijaykumar KV
    Saquib Khaleel Shaikh
    Future Journal of Pharmaceutical Sciences, 6
  • [50] The Impact of the SARS-CoV-2 (COVID-19) Pandemic on Gastroenterology Training
    Pisani, Anthea
    Cremers, Isabelle
    Ellul, Pierre
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2021, 28 (06) : 379 - 384